Work

Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.7048

Authors: Ben Kent Tomlinson, Vijay Reddy, Mark S. Berger, Jennifer Spross, Renee Lichtenstein, Boglarka Gyurkocza

Institutions: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Actinium Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954669187

Cites:

Cited by: 7

Related to: 10